Overview
Aliquot reports the narrow evidence type and limitations without turning the source into a benefit claim or dosing recommendation.
The source reports an elimination half-life of less than three hours after subcutaneous administration. Aliquot withholds a single numeric estimate because the reviewed source does not provide one.
Human pharmacokinetic context
Not published
Aliquot has not published a route-matched human half-life statement for this entry.
Half-life is descriptive population context, not a dosing interval, a prediction of an individual's response, or a recommendation. Route-mismatched and uncited estimates are withheld.
Limitations
- The reviewed human evidence is limited and older.
- A less-than threshold is not converted into an exact half-life.
- A study estimate does not predict an individual's response.
Related calculation tools
Aliquot's browser-only tools transform values you already have. They do not select a compound, suggest an amount, provide presets, or store your entries.
Sources
- Pharmacokinetics of thymosin alpha 1 in healthy volunteers Limited route-specific human pharmacokinetic context.
- Drugs@FDA: FDA-approved drugs Regulatory database consulted; no approval conclusion is asserted.
- Aliquot compound library methodology Editorial scope and withholding rules.